Candel

Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight to 2030 - Regulatory Approvals and Pharmaceutical Investments Driving Market Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 五月 27, 2024
FDA, Pharmaceutical, Health, Oncology, Pembrolizumab, Patient, Nanoparticle, Oncolytic virus, Immunotherapy, Astellas Pharma, NRG, Laboratory, Glioma, Investment, Candel, H101, Immune system, Bristol Myers Squibb, Therapy, Government, Head, Snow, Breast cancer, Optimism, Genelux Corporation, Growth, PD-1, Cancer, Potyvirus, Irinotecan, Pancreatic cancer, EMA, Melanoma, Research, Fast Track, Attention, Merck, Oncos, Gastrointestinal cancer, OH2, Roche, Indication, Virus, PD-L1, Antibody, Quality of life, Vaccine

The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering.
  • As the global medical community continues to advance targeted cancer therapies, oncolytic virus immunotherapy has emerged as a seminal player in this dynamic field.
  • Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion by 2030
    Oncolytic Viruses Immunotherapies Clinical Trials by Company, Indication & Phase
    Comprehensive Insight on Oncolytic Virus Immunotherapies in Clinical Trials: > 180 Therapies
    Cancer endures to be a relentless adversary, challenging both patients and the medical community across the world.
  • Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy.

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

Retrieved on: 
星期三, 五月 22, 2024
MD, Candel, Conference, Patient, Doctor of Philosophy, News, CADL, Therapy, Webcast

NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m.

Key Points: 
  • NEEDHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 5:30 p.m.
  • ET.
  • A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candeltx.com .
  • A replay of the webcast will be archived for up to 90 days following the session date.

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

Retrieved on: 
星期二, 三月 5, 2024
Patient, Therapy, CADL, AACR, Abstract, Candel

NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA.

Key Points: 
  • NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, CA.
  • The presentation will describe the second candidate from the enLIGHTEN™ Discovery Platform, a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors.
  • This abstract presentation at AACR accelerates the milestone associated with the unveiling of the second enLIGHTEN™ program, which was originally planned for the third quarter of 2024.
  • Presentation details are as follows:
    All regular abstracts are available for viewing via AACR’s online itinerary planner, located here .

American Brain Tumor Association Announces New Board of Directors Officers and Members

Retrieved on: 
星期二, 二月 27, 2024
International law, Prostate cancer, Candel, Cancer, Hospital, IPO, Doctor of Philosophy, Partner, Therapy, Texas Children's Hospital, Patient, ABTA, Baylor College of Medicine, American Brain Tumor Association, Harvard Medical School, Brain, Research, Boston Children's Hospital

CHICAGO, Feb. 27, 2024 /PRNewswire/ -- The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors.

Key Points: 
  • CHICAGO, Feb. 27, 2024 /PRNewswire/ -- The American Brain Tumor Association announced today the appointment of officers and new members to serve as the Board of Directors.
  • They will advance the ABTA mission under the leadership of Ram Subramanian, Board Chair, and Ralph DeVitto, President and CEO.
  • "Over the past year, the American Brain Tumor Association has experienced tremendous growth, demonstrating the impact of our board's vision and commitment," DeVitto said.
  • The 2024 ABTA Board of Directors Officers and Members:

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
星期四, 十一月 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Retrieved on: 
星期六, 十一月 4, 2023
Research, Arm, Society for Immunotherapy of Cancer, Intelligence, HSV, Therapy, Enlightenment, ICI, Herpes simplex virus, CADL, MD, Doctor of Philosophy, Nature, SITC, Immunotherapy, Neoplasm, Biology, Drug discovery, Machine learning, Annual general meeting, Tumor microenvironment, Bone marrow, Patient, Toxicity, Content discovery platform, Vaccine, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.

Key Points: 
  • “We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • “Tumor resistance to immunotherapy is driven by multiple mechanisms, which are heterogeneous in nature,” said Francesca Barone, MD, PhD, Chief Scientific Officer at Candel.
  • “The Alpha-201-macro1 preclinical data presented today support the utility of local delivery of an immunologically active, multimodal agent as a potential alternative to systemic therapy.
  • We are excited to leverage the enLIGHTEN™ Discovery Platform to optimize the immunostimulatory payload of this agent for activation of innate immune surveillance with the goal of maximizing its therapeutic potential.”
    Further details from the posters are available on the Candel website at: www.candeltx.com/media

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
星期五, 十一月 3, 2023
Survival, Standard of care, Society for Immunotherapy of Cancer, CADL, Injection, Doctor of Philosophy, CA19-9, Poster, CD8, Pancreatitis, SITC, B cell, Cancer, Chemoradiotherapy, Recurrence, Annual general meeting, Pancreatic cancer, SOC, Tumor microenvironment, Therapy, Patient, Toxicity, MS, Vaccine, Pharmaceutical industry, Candel, MD, Fellow of the Academy of Medical Sciences, Immunotherapy, PDAC

Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.

Key Points: 
  • Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “Given frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,” said Garrett Nichols, MD, MS, Chief Medical Officer of Candel.
  • “We are encouraged by the improved survival associated with CAN-2409 for the treatment of borderline resectable PDAC, demonstrated for the first time in a randomized clinical trial.
  • Only one patient randomized to control SoC chemotherapy remained alive at data cut-off (alive at 43 months).

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Retrieved on: 
星期三, 十月 18, 2023
Principal, Survival, Standard of care, Trial of the century, Harvard Medical School, Manuscript, Break, CADL, MD, Doctor of Philosophy, HGG, Disease, Nestin, Clinical trial, Immune system, Antibody, SOC, Tumor microenvironment, Therapy, Patient, Hospital, Glioblastoma, Toxicity, Seroconversion, Pharmaceutical industry, Vaccine, Medical imaging, Candel, Fellow of the Academy of Medical Sciences, Brigham, Nature

The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .

Key Points: 
  • The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .
  • Importantly, CAN-3110 treatment was associated with a significant increase in immune cells in the tumor microenvironment and in the peripheral blood.
  • Of importance, patients with recurrent HGG who had pre-existing antibodies to HSV-1 virus (66% of the patients) had a median overall survival of 14.2 months.
  • Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients.

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

Retrieved on: 
星期三, 九月 27, 2023
Survival, Pancreatic cancer, SITC, Immunotherapy, Society, Therapy, CADL, Patient, Annual general meeting, Pharmaceutical industry, Candel

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancer

Key Points: 
  • One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancer
    NEEDHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced the Company will present three posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting taking place November 3-5, 2023 in San Diego, CA and virtually.
  • Presentation details are as follows:
    Further details from the presentations will be available following the events on the Candel website at: www.candeltx.com/media

Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Retrieved on: 
星期二, 九月 26, 2023
Survivor, ICIS, University, ICI, Cohort, Overalls, Survival, Clinical trial, OS, Quality of life, Lung cancer, National Cancer Institute, University of Pennsylvania, NK, Research, Toxicity, Doctor of Philosophy, Associate, PACT, ASCO, CIMAC, Patient, Perelman School of Medicine at the University of Pennsylvania, Immune system, Aggarwal, Toxic epidermal necrolysis, MPH, Therapy, CADL, Tumor microenvironment, Safety, Disease, Pharmaceutical industry, Vaccine, Candel, NSCLC, Fellow of the Academy of Medical Sciences, MD

These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al.

Key Points: 
  • These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al.
  • Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024, assuming mature data at that time.
  • “We are very encouraged by the initial survival data, particularly for Cohort 2 which enrolled patients whose disease progressed despite receiving anti-PD(L)1 treatment.
  • I look forward to the maturation of these overall survival data and expected readout in Q2 2024.”